Interleukin Genetics Regains Compliance with OTCBB Requirements
07/07/2005
INTERLEUKIN GENETICS REGAINS COMPLIANCE WITH OTCBB REQUIREMENTS
WALTHAM, MA – JULY 7, 2005 – Interleukin Genetics, Inc. (OTCBB: ILGN) today announced that it has been informed by the NASD that the Company has been found to satisfy the requirements for the continued eligibility of its common stock to be quoted on the OTCBB. As a result, the hearing scheduled for July 14, 2005 to hear the Company’s appeal of an earlier determination that the common stock was no longer eligible for quotation has been canceled. The Company’s stock symbol on the OTCBB has been returned to “ILGN”.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease and weight management. Interleukin expects that these programs will lead to products that will personalize the selection of nutritional and therapeutic products and enable consumers to manage their health care. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in our annual report on Form 10-K, our Form 10-K/A, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Fenel M. Eloi (781) 398-0700